14 February 2019


CeBIL researchers Timo Minssen, Helen Yu and Sven Bostyn recently visited the US to discuss various CeBIL projects with US core partners. This included meetings concerning CeBIL’s “black box” medicine projects at the Petrie-Flom Center for Health Law Policy, Biotechnology, & Bioethics, as well as discussion regarding CeBIL’s projects on antimicrobial resistance with the PORTAL research group at Harvard Medical School & Brigham’s Women hospital. CeBIL Director Timo Minssen also presented CeBIL’s work for CARB-X Director Professor Outterson’s research team at Boston University, and at a “Biosimilar Innovation” conference at the University of California-Irvine. His US trip was concluded by a meeting with gene editing pioneer Feng Zhang at the Broad Institute.